新华制药获二十碳五烯酸乙酯软胶囊注册证书 助力心血管疾病治疗新突破

报告大厅
05 Jun

中国报告大厅网讯,近年来,随着全球慢性病发病率攀升,血脂异常已成为威胁人类健康的重要因素。在心血管疾病防治领域,降低高甘油三酯血症患者的代谢风险成为临床研究重点方向。2025年6月5日,新华制药(股票代码:000756)宣布其自主研发的二十碳五烯酸乙酯软胶囊获得国家药监局批准上市,这一创新制剂将为重度高甘油三酯血症患者提供新的治疗选择,同时拓展公司在心血管药物领域的市场布局。  一、新型血脂调节...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10